Axogen Corporation

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Axogen Corporation sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 1 currently recruiting 3 completed later-stage tilt top decile by trial count

Axogen Corporation: 10 sponsored US clinical trials, 1 recruiting.

Axogen Corporation sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 3 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cavernous Nerve Injury, with 1 trials.

Top-decile sponsor footprint

Axogen Corporation ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 4

A Prospective, Randomized, Assessor-Blinded, Multicenter Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve Reconstruction

NCT07657182
ACTIVE NOT RECRUITING NA

Nerve Protection Evaluation: Revision Cubital Tunnel Syndrome Decompression

NCT06117501
ACTIVE NOT RECRUITING NA

Tolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends

NCT04865679
ACTIVE NOT RECRUITING

Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction

NCT01526681
TERMINATED

Surgical Treatment of Chronic Neuropathic Pain

NCT04287075
TERMINATED

Registry of Avive® Soft Tissue Membrane Utilization in Selected Applications of Acute Trauma of the Upper Extremity

NCT03943134
COMPLETED NA

Study of AxoGuard® Nerve Cap and Neurectomy for Treatment of Symptomatic Neuroma & Prevention of Recurrent Neuroma Pain

NCT03940963
COMPLETED Phase 3

Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair

NCT01809002
COMPLETED Phase 4

Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer

NCT00953277
TERMINATED NA

A Comparative Post-marketing Study of Commercially Available Peripheral Nerve Gap Repair Options

NCT00948025

Phase Distribution

PhaseTrial count
Phase 3 1
Phase 4 2

Therapeutic Areas

Cavernous Nerve Injury 1
Chronic Nerve Pain 1
Symptomatic Neuroma 1
Recalcitrant Cubital Tunnel Syndrome 1
Recurrent Cubital Tunnel Syndrome 1
Nerve Reconstruction 1
Radical Prostatectomy 1
Peripheral Nerve Injury 1
Peripheral Nerve Injuries 1
Amputation 1

Where Axogen Corporation enrollment is open (later-stage tilt)

1 recruiting of 10 indexed (10% open); 3 completed (30%).

Phase mix: 3 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Cavernous Nerve Injury (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Axogen Corporation: open-pipeline peers nationwide

Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Axogen Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%10%20%30%40% Total trials Recruiting share Axogen CorporationAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAbiomedAimmune TherapeuticsAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)
Axogen Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Axogen Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Axogen Corporation page

10 registered trials is a research-attention snapshot, not an endorsement of Axogen Corporation or any single study.

  • 1 of Axogen Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Cavernous Nerve Injury is the condition Axogen Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cavernous Nerve Injury trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Axogen Corporation pipeline card: 10 registered trials from official public datasets.Report a data error.